07:00 , Sep 14, 2015 |  BioCentury  |  Emerging Company Profile

Oncolytic improvements

The use of oncolytic viruses as cancer therapeutics has been hampered by immunogenicity, limiting their use to indications amenable to intratumoral injections. ViraTherapeutics GmbH is developing a chimeric oncolytic virus that has so far been...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Financial News

ViraTherapeutics completes venture financing

ViraTherapeutics GmbH , Innsbruck, Austria   Business: Cancer   Date completed: 2015-06-24   Type: Venture financing   Raised: EUR3.6 million ($4.1 million)   Investors: Boehringer Ingelheim Venture Fund; EMBL Ventures; Austria Wirtschaftsservice (AWS)  ...